Literature DB >> 12414764

Conformational dependence and conservation of an immunodominant epitope within the babesia equi erythrocyte-stage surface protein equi merozoite antigen 1.

Cristina W Cunha1, Lowell S Kappmeyer, Travis C McGuire, Odir A Dellagostin, Donald P Knowles.   

Abstract

Equi merozoite antigen 1 (EMA-1) is an immunodominant Babesia equi erythrocyte-stage surface protein. A competitive enzyme-linked immunosorbent assay (ELISA), based on inhibition of monoclonal antibody (MAb) 36/133.97 binding to recombinant EMA-1 by equine anti-B. equi antibodies, detects horses infected with strains present throughout the world. The objectives of this study were to define the epitope bound by MAb 36/133.97 and quantify the amino acid conservation of EMA-1, including the region containing the epitope bound by MAb 36/133.97. The alignment of the deduced amino acid sequence of full-length EMA-1 (Florida isolate) with 15 EMA-1 sequences from geographically distinct isolates showed 82.8 to 99.6% identities (median, 98.5%) and 90.5 to 99.6% similarities (median, 98.9%) between sequences. Full-length and truncated recombinant EMA-1 proteins were expressed and tested for their reactivities with MAb 36/133.97. Binding required the presence of amino acids on both N- and C-terminal regions of a truncated peptide (EMA-1.2) containing amino acids 1 to 98 of EMA-1. This result indicated that the epitope defined by MAb 36/133.97 is dependent on conformation. Sera from persistently infected horses inhibited the binding of MAb 36/133.97 to EMA-1.2 in a competitive ELISA, indicating that equine antibodies which inhibit binding of MAb 36/133.97 also recognize epitopes in the same region (the first 98 residues). Within this region, the deduced amino acid sequences had 85.7 to 100% identities (median, 99.0%), with similarities of 94.9 to 100% (median, 100%). Therefore, the region which binds to both MAb 36/133.97 and inhibiting equine antibodies has a median amino acid identity of 99.0% and a similarity of 100%. These data provide a molecular basis for the use of both EMA-1 and MAb 36/133.97 for the detection of antibodies against B. equi.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414764      PMCID: PMC130086          DOI: 10.1128/cdli.9.6.1301-1306.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  21 in total

1.  Expression of Babesia equi merozoite antigen-2 by recombinant baculovirus and its use in the ELISA.

Authors:  T Tanaka; X Xuan; H Ikadai; I Igarashi; H Nagasawa; K Fujisaki; T Mikami; N Suzuki
Journal:  Int J Parasitol       Date:  1999-11       Impact factor: 3.981

2.  Generation of a mosaic pattern of diversity in the major merozoite-piroplasm surface antigen of Theileria annulata.

Authors:  M J Gubbels; F Katzer; G Hide; F Jongejan; B R Shiels
Journal:  Mol Biochem Parasitol       Date:  2000-09       Impact factor: 1.759

3.  Detection of antibodies to Babesia equi in horses by a latex agglutination test using recombinant EMA-1.

Authors:  X Xuan; I Igarashi; T Tanaka; S Fukumoto; H Nagasawa; K Fujisaki; T Mikami
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

4.  Expression of Babesia equi merozoite antigen 1 in insect cells by recombinant baculovirus and evaluation of its diagnostic potential in an enzyme-linked immunosorbent assay.

Authors:  X Xuan; A Larsen; H Ikadai; T Tanaka; I Igarashi; H Nagasawa; K Fujisaki; Y Toyoda; N Suzuki; T Mikami
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

5.  Equine piroplasmosis: production of antigens for the complement-fixation test.

Authors:  W M Frerichs; A A Holbrook; A J Johnson
Journal:  Am J Vet Res       Date:  1969-08       Impact factor: 1.156

6.  A simple method for displaying the hydropathic character of a protein.

Authors:  J Kyte; R F Doolittle
Journal:  J Mol Biol       Date:  1982-05-05       Impact factor: 5.469

7.  Validation of a competitive enzyme-linked immunosorbent assay for diagnosing Babesia equi infections of Moroccan origin and its use in determining the seroprevalence of B. equi in Morocco.

Authors:  A Rhalem; H Sahibi; S Lasri; W C Johnson; L S Kappmeyer; A Hamidouch; D P Knowles; W L Goff
Journal:  J Vet Diagn Invest       Date:  2001-05       Impact factor: 1.279

8.  Equine piroplasmosis: complement-fixation titers of horses infected with Babesia caballi.

Authors:  W M Frerichs; A A Holbrook; A J Johnson
Journal:  Am J Vet Res       Date:  1969-05       Impact factor: 1.156

9.  Evaluation of an indirect fluorescent antibody test to diagnose Babesia equi infection in horses.

Authors:  L L Callow; W McGregor; B J Rodwell; R J Rogers; G C Fraser; D F Mahoney; G M Robertson
Journal:  Aust Vet J       Date:  1979-12       Impact factor: 1.281

10.  Phylogenetic analysis of Theileria and Babesia equi in relation to the establishment of parasite populations within novel host species and the development of diagnostic tests.

Authors:  F Katzer; S McKellar; E Kirvar; B Shiels
Journal:  Mol Biochem Parasitol       Date:  1998-09-01       Impact factor: 1.759

View more
  3 in total

1.  Expression of equi merozoite antigen 2 during development of Babesia equi in the midgut and salivary gland of the vector tick Boophilus microplus.

Authors:  Massaro W Ueti; Guy H Palmer; Lowell S Kappmeyer; Glen A Scoles; Donald P Knowles
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  Development of an Indirect ELISA to Detect Equine Antibodies to Theileria haneyi.

Authors:  Reginaldo G Bastos; Kelly P Sears; Kelcey D Dinkel; Lowell Kappmeyer; Massaro W Ueti; Donald P Knowles; Lindsay M Fry
Journal:  Pathogens       Date:  2021-02-27

3.  Comparative genomic analysis and phylogenetic position of Theileria equi.

Authors:  Lowell S Kappmeyer; Mathangi Thiagarajan; David R Herndon; Joshua D Ramsay; Elisabet Caler; Appolinaire Djikeng; Joseph J Gillespie; Audrey Ot Lau; Eric H Roalson; Joana C Silva; Marta G Silva; Carlos E Suarez; Massaro W Ueti; Vishvanath M Nene; Robert H Mealey; Donald P Knowles; Kelly A Brayton
Journal:  BMC Genomics       Date:  2012-11-09       Impact factor: 3.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.